Opinion
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Active Surveillance for Intermediate-risk Prostate Cancer, with Michael Leapman, MD, MHS
2
The Significance of KEYNOTE-905 in Muscle-Invasive Bladder Cancer
3
Christof Vulsteke, MD, PhD, breaks down findings, implications of KEYNOTE-905
4
Additional CREST data shed light on imAEs with sasanlimab plus BCG
5
